BACKGROUND: CD44 and aldehyde dehydrogenase 1 (ALDH1) are considered putative markers of highly tumorigenic cells (i.e., cancer stem-like cells) in head and neck squamous cell carcinomas. This small subset of cells is believed to be the primary responsible for tumor initiation and progression. The objectives of this study were (i) to evaluate the patterns of CD44 and ALDH1 expression in the tumor center and in the invasive front, as well as in adjacent non-tumor epithelium, and (ii) to correlate these findings with clinical parameters. MATERIALS AND METHODS: The sample comprised 44 patients with primary head and neck squamous cell carcinomas. Hematoxylin and eosin (HE) staining was used for histopathological tumor grading and for morphological analysis of adjacent non-tumor epithelium. Semiquantitative analysis was performed in histological sections immunostained for CD44 and ALDH1. RESULTS: ALDH1 immunostaining in the invasive front showed positive association with tumor size, regional metastasis, tumor histopathological grading, and disease progression. Moreover, expression of this marker in both tumor invasive front and adjacent non-tumor epithelium was related with more aggressive tumors. CD44 immunostaining was heterogeneous in all areas evaluated and did not show association with clinical data. CONCLUSION: Collectively, these data suggest that ALDH1 immunostaining in the invasive front and in adjacent non-tumor epithelium may help identify tumors with a more aggressive behavior, potentially contributing to improving treatment customization and the monitoring of patients with head and neck cancer. 
Introduction
Emerging evidence suggests that a small subset of cells in head and neck squamous cell carcinomas (HNSCCs) may be primarily responsible for tumor initiation and progression. This cell population has been shown to have an aggressive biological behavior, with the ability to self-renew and to generate heterogeneous lineages of cancer cells (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . These cells have characteristics that are similar to those of stem cells and have therefore been referred to as cancer stem-like cells (14) (15) (16) (17) (18) (19) .
The identification of highly tumorigenic cell populations could contribute to the development of novel therapeutic strategies and thus help mitigate the morbidity and mortality associated with cancer (3) . The combination of markers that allow the identification of these cells is known to be tumor dependent. In HNSCCs, the markers most commonly used to identify highly tumorigenic cells are CD44 and aldehyde dehydrogenase 1 (ALDH1; 2, 8, 12, 14, 20, 21) .
CD44 cells are a group of transmembrane glycoproteins that act on cell-cell and cell-matrix interactions (9, 22, 23) , having hyaluronic acid (a widely abundant component of the extracellular matrix) as the main ligand (10, 23) . The interaction between CD44 and hyaluronic acid activates essential characteristics of tumor progression, e.g., cell proliferation, survival, migration, and invasion (1, 10, (24) (25) (26) . Some studies have reported a relationship between CD44 immunostaining results and tumor behavior (9, 11, 24) .
Aldehyde dehydrogenase 1, in turn, is a cytosolic enzyme whose main function is to convert retinaldehyde into retinoic acid in retinol metabolism (27) . The by-products of this metabolic process increase the self-renewal ability of mesenchymal stem cells (27, 28) . ALDH1 activity is found in neoplastic cells, which show proliferative ability similar to that observed in stem cells and tumors with aggressive clinical behavior (5, 9, 12, 17, 21, (27) (28) (29) (30) (31) .
While many studies have demonstrated that ALDH+ CD44+ cells are highly tumorigenic, it remains unknown whether the spatial distribution of these cells within human tumors can be correlated with clinical outcomes. This finding could be very useful in planning the postoperative clinical management of patients with HNSCC.
Therefore, the primary objective of this study was to assess the spatial distribution of CD44+ and ALDH1+ cells in two different areas of HNSCCs (tumor center and invasive front) and also in adjacent non-tumor epithelium in specimens obtained from surgically treated patients. Possible associations between immunostaining data and clinical parameters were also investigated.
Materials and methods

Patients
Our sample comprised 44 patients treated at the Head and Neck Surgery Outpatient Clinic of Hospital de Cl ınicas de Porto Alegre (HCPA). All patients presented with primary HNSCC and had not undergone chemotherapy or radiotherapy before surgery. Patient data, including gender, age, ethnic origin, and exposure to risk factors, were collected in an interview. Tumor location, size, regional and distant metastasis (pTNM; 32), treatment protocol, and 3-4-year follow-up data were also recorded. Outcome was classified as failure (local, regional, or distant metastasis and death due to tumor) and disease-specific survival. This study was approved by the Research Ethics Committee of the institution of origin (protocol no. 09-315).
Immunohistochemistry
Paraffin blocks containing tumor center, invasive front, and non-tumor epithelial specimens were selected for analysis. Three 3-lm-thick sections were serially cut, of which two were used for CD44 and ALDH1 immunostaining and one for hematoxylin and eosin (HE) staining. Antigenic recovery was performed using Dako retrieval solution, citrate buffer pH 6.0 (Dako, Carpinteria, CA, USA), in water bath. Anti-CD44 antibody (clone EPR1013Y, rabbit, Abcam, Washington, DC, USA) was diluted at 1:100, and anti-ALDH1 antibody (clone 44, mouse, BD Transduction Laboratories, Franklin Lakes, NJ, USA) at 1:50. Nonspecific, isotype-matched IgG was used as a negative control.
Histological analysis
Hematoxylin and eosin-stained slides were graded according to the criteria set forth by Bryne et al. (33) , into good, moderate, and poor prognosis. Non-tumor epithelial tissue located adjacent to HNSCC was classified according to morphological characteristics into unaltered tissue, epithelial hyperplasia, hyperkeratosis, acanthosis, and epithelial dysplasia. Epithelial dysplasia was defined as the presence of structural and cytological abnormalities confined to epithelial layers, without invasion of other tissues. CD44 and ALDH1 immunostaining was assessed in the entire area available, in both tumor and non-tumor epithelia. Cells presenting brown staining in the membrane and cytoplasm/ nucleus were considered positive for CD44 (Fig. 1) and ALDH1 (Fig. 2) , respectively.
Immunohistochemical analysis was performed on both the invasive front and tumor center. The invasive front was defined as the deepest cancer cell islands (Figs 3d and m). Tumor center analysis focused on cancer cell islands located in the central region of the lesion, discarding areas of necrosis (Figs 3g and p). Adjacent non-tumor epithelium was considered normal when CD44 expression was observed in basal and parabasal layers, but not in superficial layers ( Fig. 3L; 34) .
Tumor markers CD44 and ALDH1 were semiquantitatively scored according to the proportion of cells stained in the whole sample as follows: 0, negative; 1, <5% of positive cells; 2, more than 5%; 3, 10-90%; and 4, more than 90% of positive cells (35) . As the statistical analysis did not show differences in comparisons using four vs. two scores, CD44 and ALDH1 results were further classified into two groups, namely positive (more than 5% of cells stained; Fig. 3B ,C, E,F,H,I) and negative (less than 5% of cells stained; 
Data analysis
All analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 18. Results were tested for normality and revealed a normal distribution of data. Associations between CD44/ALDH1 staining results in the three regions assessed and clinical parameters were assessed using Pearson's chi-square test and Fisher's exact test (significance level set at P < 0.05). Result reproducibility was confirmed over the study period by selecting one of every 20 slides (HE, CD44, and ALDH1) for reassessment after a 7-day interval (j > 0.7). Examiners were blind to the site of origin of each specimen.
Results
Mean patient age was 58 years (range: 37-78 years), and there was a male predominance of 86.4%. Most patients were currently or formerly exposed to tobacco and alcohol. Detailed clinical data are summarized in Table 1 . Of the 44 tumors assessed, 65.9% were 4 cm in diameter or smaller (T1 and T2), and 68.2% did not present regional metastases at the moment of assessment. None of the patients presented distant metastases. Most tumors were located in the oral cavity, most frequently affecting the tongue, lower lip, and floor of the mouth (Table 1) .
Histopathological analysis revealed that 50% of the tumors were considered to be of good prognosis, 38.6% moderate, and 11.4% of poor prognosis. Most of the adjacent epithelium samples were classified as epithelial hyperplasia and hyperkeratosis (31.8% each), followed by epithelial dysplasia (18.2%). Normal epithelium was found in 13.6% of the samples (Table 1 ). Over the 3-4-year follow-up period, 68.2% of the patients were free from disease, whereas 25% showed disease recurrence/metastasis or died (Table 1 ).
An association was found between ALDH1 immunostaining results in tumor areas and in adjacent non-tumor epithelium, suggesting that ALDH1-positive tumors also tend to show ALDH1-positive non-tumor epithelium (Table 2 ). This association was not observed for CD44. Table 3 shows CD44 and ALDH1 immunostaining results in tumor and non-tumor epithelium in association with clinical parameters and follow-up data. In the invasive front, associations were observed between ALDH1 immunostaining and tumor size (T3 and T4), presence of regional metastases (N1, N2, N3), and histopathological grading (good/moderate). Conversely, ALDH1 immunostaining in the tumor center did not show any association with the parameters assessed. In adjacent non-tumor epithelium areas, an association was observed between ALDH1 immunostaining and histopathological grading and followup data: 93.8% of the patients free from disease over the 3-4-year follow-up period showed ALDH1-negative cells in adjacent non-tumor epithelium (P = 0.019). These associations were not observed for CD44.
Discussion
Highly tumorigenic cancer stem-like cells present in HNSCC have been considered responsible for the aggressive biological behavior of this tumor (1-14 , 20, 21) . Most studies available in the literature describe the use of cell culture techniques, flow cytometry, or transplantation assays in animal models to detect highly tumorigenic cells and thus assess the pathobiology of HNSCC (1, 2, 5, 6, 37). Our sample, in turn, was comprised of surgically removed human primary HNSCC specimens, and highly tumorigenic cells were identified in three different areas of the specimens using the immunostaining method. Sample characteristics, including mean age, gender, and exposure to risk factors (tobacco and alcohol use), were in line with the typical profile described for patients diagnosed with HNSCC (30, 38, 39) .
Head and neck squamous cell carcinomas cells are heterogeneous within the same lesion, i.e., their cell hierarchy allows us to find subpopulations with exclusive biological behaviors, e.g., tumor growth and metastatic potential (1, 3, 19, 33) . Our results showed positive CD44 and ALDH1 expression in both basal and suprabasal cells, which may indicate that the immunohistochemical technique here employed was not appropriate to identify cancer stem cells in HNSCCs based on these markers, as also reported by other authors (31, 34) . Moreover, no specific markers have been established for the identification of cancer stem cell subpopulations in HNSCCs, as is the case with other tumors (37) . Notwithstanding, immunohistochemistry did allow us to identify the location of positive cells in different tumoral areas (tumor center and invasive front), as well as in the different layers of adjacent nontumor epithelium. Also, our analysis revealed a positive correlation between the spatial localization of ALDH1-positive cells and clinical outcomes, especially in the identification of tumors with a more aggressive behavior, despite the method's failure identifying cancer stem cells.
Immunostaining results obtained for the two tumor areas and non-tumor epithelium showed that tumors with ALDH1-positive cells also presented positive surrounding epithelial tissues. The concept of field cancerization, according to which carcinogen-induced changes would be present in HNSCC-related non-tumor tissues before morphological alterations can be found, was first proposed by Slaughter et al. (40) and later examined by Califano et al. (41) . We believe that our finding of ALDH1-positive cells in adjacent non-tumor epithelium suggests that changes were already underway, as this enzyme tends to be present in cells with a high tumorigenic potential (12, 27, 29) .
Conversely, immunostaining results for CD44 in the two tumor areas and in adjacent non-tumor epithelium did not reveal any significant associations. No association was found between CD44 expression and clinical parameters. Notwithstanding, different results are reported in the literature with the use of other CD44-positive cell detection methods, e.g., flow cytometry (2, 37). The value of CD44 as a marker for highly tumorigenic cells has been questioned previously (26) , and some studies have suggested that it may not be relevant in early diagnosis or as a prognostic marker in HNSCCs (42, 43) .
Indeed, previous studies have shown conflicting results on the significance of CD44 expression in head and neck tumors (9, 24, (44) (45) (46) (47) (48) . Studies employing immunochemistry have shown that under-expression of CD44 standard form is a predictor of reduced survival (44, 45, 47) . In contrast, others have shown CD44 to be highly expressed in normal, dysplastic, and tumoral head and neck epithelium (11, 24, 26) . The expression of specific CD44 variants may be reduced in tumors with a worse prognosis, but overall CD44 expression is not (46) (47) (48) . Even though these varying results may be due to the use of different antibodies and assessment methods, CD44 immunostaining seems to be ineffective in detecting highly tumorigenic cells in HNSCCs. CD44 appears to be present at different stages of carcinogenesis (24, 35) . At first, CD44 binding to hyaluronic acid in the extracellular matrix stabilizes neoplastic cells in the invasive front, stimulating cell proliferation and consequently the growth of cancer cell islands (24, 25) . Single-cell invasion shows a strongly positive expression of CD44 around the entire plasma membrane (35) . Subsequently, the loss of CD44 expression suggests a second stage of tumor progression, in which cells lose their cell-cell adhesion, facilitating mobility and consequently the invasion and migration of neoplastic cells (22) (23) (24) (25) 44) .
Aldehyde dehydrogenase 1 staining in the tumor invasive front and non-tumor tissues showed positive associations with both clinical parameters (tumor size and presence of regional metastasis) and histopathological grading results. The lack of the same associations in the tumor center may be due the biological behavior of neoplastic cells in this region, i.e., less aggressive than cells of the invasive front (33) . The association of ALDH1 staining with lymph node metastasis in HNSCC has been demonstrated previously (30) . ALDH1-positive tumor cells have high tumor-initiating ability and also high invasion ability, properties that may be related to regional metastasis. In this sense, ALDH1 immunostaining may help identify tumor cells with an undifferentiated phenotype, suggestive of tumors with a stronger ability to invade surrounding tissues and develop metastases (13, 21, (27) (28) (29) (30) .
In our sample, ALDH1 immunostaining results were similar in tumor tissues and in non-tumor epithelium, suggesting that this marker could be used as an instrument to predict higher or lower risk of disease recurrence. Moreover, an association was observed between ALDH1 immunostaining in non-tumor epithelium and follow-up data: Of all adjacent epithelium specimens testing positive for ALDH1, 35.7% showed metastases, local recurrence, or death within 3-4 years, whereas 93.8% of disease-free patients stained negative for ALDH1. This finding indicates the presence of cells with a highly tumorigenic potential even in cancer-free zones. In conclusion, CD44 and ALDH1 expression did not show a distinct spatial distribution pattern when invasive front and tumor center specimens were compared. Furthermore, while CD44 expression did not show a clear correlation with clinical outcomes, ALDH1 staining correlated well with tumor size, presence of regional metastasis, and histopathological grading. These results demonstrate that ALDH1 is predominantly found in more aggressive tumors, in both tumor areas and adjacent non-tumor epithelium, and may therefore be useful in improving treatment customization and the postoperative clinical management of patients with head and neck cancer. 
